{"name":"Viriom","slug":"viriom","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AV5080","genericName":"AV5080","slug":"av5080","indication":"Tick-borne encephalitis (TBE)","status":"phase_3"}]}],"pipeline":[{"name":"AV5080","genericName":"AV5080","slug":"av5080","phase":"phase_3","mechanism":"AV5080 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.","indications":["Tick-borne encephalitis (TBE)","Other flaviviral infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVXpCV25oMmg5aTBBVVZ2cGd1OG9aLUR0aTJJQ2ZHeXQ2TWdHU0gweVlLZ2dXbmVhLXlCaG55X1d2M18yT1J2bk5QbEtXY0JoYWZtbmVrWV96MHVBcW4yOWNaMDhVbWtDTGh1Vkc1UG05em1PaGhVYVRpcFZmbUhCaXBYVU5NcGNXbGljY29fSVUwTzhabmUzSDg3OXk1RS1zc0drUFBPSXJ5WFVyVmZ4RXRVSG92Tk11cFJoVG5sdmFxZTNJdk4wNmQ1VTBGSnNUZ09fbXN4NGpRZEgxYUJzZURPclZ3WnFjNlhaclEwWXBCSGZqdC1QMzNaMXU?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxPdVlfbW4wVVdVMmlIaWp3dVFLaF9hUnBDRk9NbVU4bHIxTVRxVlZtMmtCRFlvbzVFQkI0eVhSNm44dUhwOFNkSUVZSlZmNlJuZGpkLUVuTFZ2SWhtTGlXNGFmUHpPbW1HX0NHbER2TE9NcnQwbTljV1hhYjdBZ1liUUtMejhCYnhKcHhOMWRjelFtaWxSUVBDVlF3cmJDRkd0T0Q5QzNiUHFDdVZFV1pzYlpFckRVZEtDSVFKSHkwTkEwOGNOMTZaeUpvMGRJcGZTM2RlcVdON2xteFF3ZjVZZEVSbHpHOEF1QlFOeVo5MUVxYW9aZDN3eWM0TUlRSFNIcHo2Wm1oV2R0LVUzYXpVUllJMk1WSU5XQThuUWttampNNFlXSXBqWGRwazJUVFlSTktXb2JvcEJwd2QzZlA1cVl4dXYzRURyaGc?oc=5","date":"2025-10-07","type":"trial","source":"Business Wire","summary":"Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2025 - Business Wire","headline":"Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNalRLOUlrSnpqbkpPZmlJUTVwSlVFYWtuZ2VJN1FjdkxIUDZ5UFpFUmtjM0ptU2h4bVJ2UHEwQnNraGtfYk10MG1MNjNJU2VRX2lhUi1wdHQtTVRFLWphUjgwd1NTbmI2ckZWcHcxVFFaNVN6V3FucUtfRnNXVHBuNkxIcjZib0dKcWs1eXlPMEtPZTFXMG9hNXN5dl82M20wemc1dWNKVXI3bERXdENPckFtLU51Qk1VZmdJTjRTQTRHU0UtU3JHdHpSaS1zSlFxTGd4OUNXSS1yNVhoWFBOZU5ueFNVcW1mY3dkZ01kSHVmd3U3b2xaQWVJVlJNbjFzUGJ0TjY3VVRfb2t5NEQ2MnJKOGd5TFNWQ2REbGRQZ3g3b3l5anBiVTRqaHR2bVdP?oc=5","date":"2025-08-20","type":"pipeline","source":"PR Newswire","summary":"HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight - PR Newswire","headline":"HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOSXVhbkk3Sk9KdFJ3ME5Ea1hvR0p2SU1MOVU5T0p1cGZMcnVtaTR4R0JXdXFBalhWNU16OWIwa3FRNmZ4TUNaTjMtV0FoUmRIVV92SGZ4YmRSVm5LOEhreURidWI1MWdaU3ktTDJ4SDMwdGlVOXNYbkZMbEs4UG9Hb2NRMDl0NGRCMGFaZXZUZVNyUGEyWk5wMzFBeFU5SHdzbF9rSWVBcW_SAa4BQVVfeXFMUF95a1JzZHJYcHRxRjNJXy10UEx1Zlp3SklJeGVJVjc0aFVnME1LeGJKUXdQVE9XQjFsbmxfVEVCTnRReE9jZkFuR1pucUF1aGNFbWstSlVib21uZGJhNWR1c0JVeDlFMDBwV0NkYkFLQlRCSWc1VHlUREo4VjI5NlZxeThpMGNtZ3VweXhLTDlrWDBtNU14R0tvYXpvV3YzSGlHbWZIbXlXY2lFTDJB?oc=5","date":"2024-09-09","type":"pipeline","source":"medicaldialogues.in","summary":"CDSCO issues Cancelled Lincence List of importers - medicaldialogues.in","headline":"CDSCO issues Cancelled Lincence List of importers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQVGVWMkpiY3NyYTdESjFxeDF6RnRzU3VWV3R5aGFwdzhLTDMwRDVhcDZ4dlVFMWlhUXBCQ2ZnV2ExbmQyY0JXdzJkanNqSDhxS3MwZmxtVzVwZGh3dGw2NGFEMWFRTGwtbVUxUjhGTl9NM2RwQnFnSElfUU5YZlYtNXZkUWZTQmhOQy1sVUxxdDlrVWVhTXM0a0dtaUdlQTlUQ3ZMYXBR?oc=5","date":"2018-09-17","type":"pipeline","source":"BioSpace","summary":"Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO - BioSpace","headline":"Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}